Abstract 425P
Background
In Indonesia, traditional medicine is still trusted, especially as a cancer therapy. Cancer treatment, which has many side effects, triggers the patient's anxiety. The patient's decision may contradict the advice of a health professional, affecting the prognosis of cancer. Health professionals are responsible for delivering explicit and adequate information to prevent misinformation that may affect decision-making for patient care. The Universitas Sebelas Maret Trust and Readiness Assessment for Cancer Patients (UNS – TRAfCP35) is an instrument designed to assess a patient's understanding of cancer, confidence in alternative medicine, and a patient's confidence in medical therapies. This study aims to see the validity and reliability of UNS – TRAfCP35 in assessing patients' understanding of cancer, trust in alternative medicine, and trust in medical treatment for cancer patients in Indonesia.
Methods
This is a cross-sectional hospital-based study conducted on 100 patients at Dr. Moewardi Hospital, using UNS-TRAfCP35. The questionnaire consisted of 35 questions divided into 3 parts: 15 questions regarding patients' understanding of cancer, 8 questions regarding their belief in alternative medicine, and 12 questions about patients' trust in medical treatment. Validity and reliability were used using Pearson and Cronbach alpha.
Results
Validity tests showed that the understanding of cancer (r = 0.236–0.456), the patient's confidence in alternative medicine (r = 0.301–0.688) and the patient's confidence in medical care (r = 0.324–0.765) had r > 0.196. Reliability tests showed that the questions from each section had Cronbach alpha values of 0.712, 0.830, and 0.844, respectively. Alfa Cronbach > 0.60. The values indicate that all questions in the questionnaire are valid, reliable, consistent, and qualified for further analysis for the treatment of cancer patients.
Conclusions
This study shows that UNS – TRAfCP35 is valid and reliable for assessing patients' understanding of cancer, trust in alternative medicine, and medical care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
419P - Breast arterial calcifications on mammogram and its clinical implications
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06
420P - Predictive factors of post-operative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: A retrospective cohort study
Presenter: Chito Cabiling
Session: Poster viewing 06
421P - The association between early changes in neutrophil-lymphocyte ratio and survival in patients treated with immunotherapy
Presenter: Deniz Can Guven
Session: Poster viewing 06
422P - Molecular mechanism in prostate cancer with TP53 mutation
Presenter: Bin Hu
Session: Poster viewing 06
423P - Maintaining a national essential medicine list for cancer in Malaysia: Where do we stand?
Presenter: David Lee
Session: Poster viewing 06
424P - The Storm: Paraneoplastic leucomoid reaction - A bad prognostic factor
Presenter: Abdullah Al Mamun Khan
Session: Poster viewing 06
426P - Safety of Sputnik V COVID-19 vaccine in cancer patients receiving chemotherapy: An observational study
Presenter: Alexey Rumyantsev
Session: Poster viewing 06
427P - Oncology combination therapies in Asia-Pacific markets: What are the current access challenges?
Presenter: Gayathri Kumar
Session: Poster viewing 06
428P - Clinical characteristics, laboratory parameters, and hospital outcomes of COVID-19 among patients with and without cancer: A retrospective cohort study
Presenter: PRASHANT SIROHIYA
Session: Poster viewing 06
429P - Cancer and COVID-19 in India: Assessing the impact in a nationwide survey
Presenter: Bharti Devnani
Session: Poster viewing 06